唐方教授脏腑辨证治疗小儿急性咳嗽经验

小儿急性咳嗽作为儿科常见病,因小儿脏腑娇嫩、形气未充,具有发病急骤、传变迅速的病理特点,故易出现各种变证,建立完善的小儿急性咳嗽诊治体系就显得尤为重要。因咳嗽病程不同,病邪部位有异,辨证论治之法亦有不同,唐方教授通过多年临床实践归纳和总结出小儿咳嗽从"肺胃肝三脏"治疗理论。该理论以脏腑辨证为基础,具有紧抓主症、用药考究、灵活加减的特点。临床用药加减则依据肺主宣发肃降,故多予炙麻黄、桔梗开宣肺气,予桑白皮、葶苈子降气止咳,且小儿生理特点为"脾常不足",故而过量进食之后,损伤脾胃,造成肺胃热盛同病,胃多气多血之腑,故予红景天、地龙、牡丹皮活血凉血清热。通过对临床医案的分析,进一步阐释从"肺胃肝三脏"治疗理论,从而为小儿咳嗽的临床诊治工作提供有益借鉴。     

数据挖掘法探讨周珉教授治疗原发性肝癌用药规律及经验总结

[目的]数据挖掘法分析周珉教授治疗原发性肝癌的中医用药规律，探讨相关病机并进行经验总结。[方法]收集2016年2月—2018年5月周珉教授门诊期间治疗原发性肝癌的方剂，运用“中医传承辅助系统（V2.50）”进行数据挖掘，并结合周珉教授临床经验，进行原发性肝癌病机探讨及用药规律分析。[结果]共收集治疗原发性肝癌方剂176首，涉及中药235种，列出方剂中的高频药物及组合规律。[结论]总结原发性肝癌以“湿热痰毒、气阴两伤”为基础病机，“清热化湿、健脾养阴”治则贯穿原发性肝癌治疗始末，同时，根据疾病不同发展阶段及治疗措施，权衡“扶正”与“祛邪”的主次分配，斟酌应用“攻毒散结”“行气化瘀”等治法，以达到改善患者生活质量、延缓疾病进展的目的。     

殷克敬教授治疗产后缺乳临床经验

介绍全国名老中医殷克敬教授治疗产后缺乳的临床经验,为临床广泛推广应用提供借鉴。殷克敬教授认为缺乳的病因无非虚实两端,虚者为产后气血不足、冲任虚损、脾胃虚弱;实者为肝气郁滞而致;治疗当以"补养""通导"为法,临床采用胸部和背部推拿按摩,膻中与天池、乳根与屋翳对刺,电针少泽、内服加减涌乳汤等。治疗方法针药并用,通补兼施,气血得补,乳络得通,故乳汁自下。     

Long-Term Results of Cementless Total Hip Arthroplasty for Patients With High Hip Dislocation After Childhood Pyogenic Infection

BackgroundThe purpose of this study is to analyze the 10-year outcomes of cementless, modular total hip arthroplasty (THA) in adult patients who had high dislocation secondary to childhood pyogenic arthritis.MethodsWe retrospectively followed 56 consecutive patients who underwent cementless, modular THA for the late sequelae of childhood septic arthritis of the hip from 2001 to 2011. There were 23 men and 33 women with a mean age of 47 years (24 to 68). Of the 56 hips, 25 were classified as Crowe type III and 31 as type IV. Mean follow-up was 10.7 years.ResultsOne hip with a quiescent period of 23 years had recurrence of infection. Revision surgery was performed in 2 patients because of loosening and breakage of femoral stem and new infection with no correlation with childhood sepsis, respectively. The mean Harris hip scores improved from 44.2 points preoperatively to 87.5 points at final follow-up. Similarly, the Hip dysfunction and Osteoarthritis Outcome Score and hip pain also significantly improved at the latest follow-up. The mean acetabular cup abduction was 40.8° and the mean anteversion 27.8°, respectively. There were 5 cases of transient nerve palsy and 5 cases of intraoperative fracture.ConclusionTHA can reliably restore the abnormal anatomy and provide good results in these young and active patients who had high hip dislocation secondary to childhood pyogenic arthritis with a relatively high incidence of complications. However, these complications can be treated.     

Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week

Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer.     

Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial

Introduction/Hypothesis

Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.

临床抗青光眼药物的新进展

青光眼是致盲的主要原因之一，构成视神经的神经节细胞轴突受到多种因素的损伤，其机制尚未完全明了。青光眼最重要的危险因素是眼压升高。由于青光眼的视神经损伤尚不能直接治疗，根据目前提供的唯一已知可治疗的危险因素，可以降低升高的眼压，而眼压与房水流出通道的功能息息相关。这些方面的药物均可以影响青光眼的进展。随着医疗技术的发展以及对青光眼发病机制认识的加深，新型抗青光眼药物也应运而生，为眼科医师提供新的选择。本文将对国内外新型抗青光眼药物从机制、药理特点及临床疗效等方面进行综述。